West Pharmaceutical Services, Inc. (WST) Stock News
Follow the latest West Pharmaceutical Services, Inc. (WST) news and market headlines alongside the live WST price. Stay informed on what's moving WST.
News
Read Full Article - Read Full Article
Keith Meister Sells $61M Of Illumina Stock As Shares Slip Below Sale Price
Keith Meister, who controls the general partner of Corvex Management, sold 280,091 shares of Illumina Inc (NASDAQ:ILMN) for $61.1 million on Nov. 9, 2026.Illumina shares were $208.85 on Friday, 4.25% below the $218.12
- Read Full Article
10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study
10x Genomics announced that Fudan University Shanghai Cancer Center and Shanghai Precision Diagnostics will use its Xenium platform in a 24-month breast cancer biomarker study analyzing tumor biopsies from 500 patients. The collaboration aims to identify biomarkers predicting treatment response to neoadjuvant therapy, potentially advancing personalized cancer diagnostics. TXG stock has surged 264.7% year-to-date, outperforming broader markets.
- Read Full Article
Here's Why You Should Retain AMN Stock in Your Portfolio for Now
AMN Healthcare (AMN) is well-positioned for growth driven by strong healthcare staffing demand, MSP opportunities, and technology investments, with Nurse and Allied revenues rising 27% in Q3. However, the stock faces headwinds from visa delays affecting international nurse placements, pricing pressures, and weakness in Physician and Technology segments. The company holds a Zacks Rank #3 (Hold) rating despite surging 140.5% year-to-date.
- Read Full Article
Merit Medical Reports Strong Real-World Data for WRAPSODY Device
Merit Medical Systems announced positive real-world clinical data from its WRAPSODY Cell-Impermeable Endoprosthesis, demonstrating 92.7% six-month target lesion primary patency and 76.7% access circuit primary patency, both exceeding WAVE trial results. The device received FDA approval in December 2024 and is now being commercialized in the U.S., with ongoing registry studies expected to generate comprehensive clinical evidence supporting wider physician adoption in the growing dialysis access market.
- Read Full Article
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CONMED (CNMD) is positioned for growth through its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, supported by expanding surgical adoption and favorable legislation. However, the company faces near-term challenges including U.S. orthopedic weakness, tariff pressures, and OEM business volatility. 2026 EPS estimates were raised to $4.58 per share despite headwinds.
- Read Full Article
Global Injectables Market is Anticipated to Surpass USD 1 Trillion Mark by 2034 | DelveInsight
The global injectables market is projected to grow from USD 765 billion in 2025 to USD 1.6 trillion by 2034, with a CAGR of approximately 9%. Growth is driven by rising adoption of biologics, biosimilars, GLP-1 therapies, and advances in drug-delivery technologies like prefilled syringes and auto-injectors. North America leads with 39% market share, while Asia-Pacific represents the fastest-expanding region. Key developments include West Pharmaceutical Services' Dublin expansion and Fresenius Kabi's U.S. manufacturing collaboration.
- Read Full Article
Here's Why You Should Retain INSP Stock in Your Portfolio for Now
Inspire Medical Systems (INSP) is positioned for solid growth despite a 32.5% year-to-date stock decline. The company faces near-term headwinds from $120 million in annual coding and reimbursement disruptions, but benefits from strong Inspire V adoption, improved clinical evidence, and a new CPT code effective in 2028. Project Horizon initiatives are expected to support low-single-digit revenue growth in 2027, though GLP-1 adoption and international weakness remain concerns.
- Read Full Article
Waters Gains FDA Clearance for Flow Cytometry Tests for Blood Cancers
Waters Corporation received FDA 510(k) clearance for its BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test, ready-to-use flow cytometry tests designed to diagnose B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The tests deliver 96.3% sensitivity and 98.2% specificity, reduce manual steps by 95%, and are expected to launch commercially in spring 2027. The stock rose 2.9% following the announcement.
Explore More US Stocks
Data Sources and Disclosures
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to WST, including RealStocks and Stock Futures.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.


